Companies › Onconic Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Gastroenterology, Other, Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JP-1366 unclear - likely proton pump inhibitor or gastric protection agent | – | Phase 3 | Peptic Ulcer; Drug Drug Interaction (DDI) | Aug 2027 |
| JPI-547 | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | Apr 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07265466 | JP-1366 | Phase 1 | Drug Drug Interaction (DDI) | Other | Mar 2026 |
| NCT06439563 | JP-1366 | Phase 3 | Peptic Ulcer | Gastroenterology | Aug 2027 |
| NCT05257993 | JPI-547 | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Apr 2030 |
No annotated target.
–
J-Pharma SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Lee's Pharmaceutical Zhejiang Doer Biologics InventisBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.